<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04502849</url>
  </required_header>
  <id_info>
    <org_study_id>25.07</org_study_id>
    <nct_id>NCT04502849</nct_id>
  </id_info>
  <brief_title>Apoptosis Proteins and Endothelial Dysfunction in Patients With Atherosclerosis of Peripheral Arteries</brief_title>
  <official_title>Comprehensive Assessment of Indices of Apoptosis and Endothelial Dysfunction and Methods of Their Correction in Patients With Atherosclerosis of Peripheral Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ryazan State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ryazan State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modern vascular surgery has various options for open and endovascular surgical methods aimed&#xD;
      at treating patients with peripheral arterial diseases. Despite the achievements of vascular&#xD;
      surgery, the occurrence of postoperative complications levels out the success of surgical&#xD;
      interventions and requires repeated surgical interventions. The most common complication is&#xD;
      stenosis of the reconstruction zone, which develops in approximately 50% of operated&#xD;
      patients.&#xD;
&#xD;
      At present, the apoptosis system plays an equally important role in the development of&#xD;
      restenosis of the intervention zone. It has been recognized as a central component in the&#xD;
      pathogenesis of atherosclerosis, in which the Bcl-2 family of proteins is activated. It is a&#xD;
      group of cellular proteins that are important regulators of the apoptosis system in cells&#xD;
      located in the mitochondrial membrane. In experimental animal models, it was shown that&#xD;
      apoptosis after angioplasty of the coronary arteries proceeds in the form of two waves. After&#xD;
      injury to the vascular wall, during the first hours, it is activated in the smooth muscle&#xD;
      cells (SMC) of media, and after two weeks in the cells of the neointima, by the 28th day it&#xD;
      almost completely stops. A decrease in the apoptosis index in the postoperative period may&#xD;
      cause the development of restenosis of the reconstruction zone. The use of antioxidants, for&#xD;
      example, alpha-tocopherol acetate, in the first month of the postoperative period, at the&#xD;
      time of activation of apoptosis, inhibits the latter and reduces the proliferative activity&#xD;
      of the SMC media and neointima. One month after surgery, delayed apoptosis of vascular wall&#xD;
      cells can lead to the development of neointima and restenosis. In this case, the use of drugs&#xD;
      that enhance apoptosis, for example, lipophilic statins, calcium channel blockers, will be&#xD;
      relevant.&#xD;
&#xD;
      Nitric oxide metabolites, depending on the concentration, can act as both an inducer and an&#xD;
      inhibitor of apoptosis. The mechanism of NO-induced apoptosis in SMC includes an increase in&#xD;
      the Bax / Bcl-2 expression ratio, which leads to the release of cytochrome C from&#xD;
      mitochondria, activation of caspase-3 and -9. In patients with atherosclerosis of the&#xD;
      peripheral arteries, proteins of the Bcl-2 family and their relationship with markers of&#xD;
      endothelial dysfunction have not been sufficiently studied, the results obtained are&#xD;
      contradictory.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      250 patients will be divided into 5 groups with follow-up period of 2 years. Blood sampling&#xD;
      for apoptosis and proliferation (Bcl-2, Bax, Fas, p53, PDGF-BB (platelet growth factor), VEGF&#xD;
      (vasculoendothelial growth factor)) and endothelial dysfunction (NO metabolites) markers will&#xD;
      be performed before,1 day after, 1 and 6 month after surgery for groups A-C and for groups D,&#xD;
      E when included into study.&#xD;
&#xD;
      Arterial wall sampling for apoptosis and proliferation (Bcl-2, Bax, Fas, p53, PDGF-BB, VEGF)&#xD;
      during surgery in group A-C patients.&#xD;
&#xD;
      Duplex ultrasound of lower limbs arteries will be performed before,1, 6, 12, 18 and 24 month&#xD;
      after surgery for groups A-D and for group E when included into study.&#xD;
&#xD;
      100 mg per os of Vitamin E 1 per day during 1 month after surgery will be prescribed to half&#xD;
      of groups A-C patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Restenosis of the reconstruction zone after surgery (detection of narrowing of the lumen of an artery or prosthesis in the reconstruction area using instrumental methods (ultrasound, angiography)).</measure>
    <time_frame>Up to 2 years after enrollment.</time_frame>
    <description>Revealing restenosis after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombosis of the reconstruction zone after surgery (detection of thrombosis in arteries or prosthesis in the reconstruction area using instrumental methods (ultrasound, angiography)).</measure>
    <time_frame>Up to 2 years after enrollment.</time_frame>
    <description>Revealing thrombosis after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression of atherosclerosis (detection of narrowing of the lumen of an arteries by atherosclerotic plaque using instrumental methods (ultrasound, angiography)).</measure>
    <time_frame>Up to 2 years after enrollment.</time_frame>
    <description>Increasing the stage of atherosclerosis (Fontaine classification).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deviations of apoptosis markers in blood and tissue homogenate (Bcl-2, Bax, FAS, VEGF, P53, PDGF-BB) from reference values.</measure>
    <time_frame>Up to 2 years after enrollment.</time_frame>
    <description>Deviation of apoptosis markers from reference values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deviations of endothelial dysfunction markers in blood (NO metabolites) from reference values..</measure>
    <time_frame>Up to 2 years after enrollment.</time_frame>
    <description>Deviation of endothelial dysfunction markers from reference values.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Group &quot;Bypass&quot; (A)</arm_group_label>
    <description>50 patients with indications for bypass surgery (chronic lower limb ischemia, stage 2b-4 Fontaine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;Endovascular&quot; (B)</arm_group_label>
    <description>50 patients with indications for endovascular angioplasty and stenting (chronic lower limb ischemia, stage 2b-4 Fontaine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;Hybrid&quot; (C)</arm_group_label>
    <description>50 patients with indications for hybrid surgery (endovascular angioplasty/stenting and bypass surgery; chronic lower limb ischemia, stage 2b-4 Fontaine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;Conservative&quot; (D)</arm_group_label>
    <description>50 patients without indications surgery (conservative treatment, chronic lower limb ischemia, stage 2b-4 Fontaine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group &quot;Healthy volunteers&quot; (E)</arm_group_label>
    <description>50 healthy subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bypass surgery</intervention_name>
    <description>Creating a bypass with graft or vein.</description>
    <arm_group_label>Group &quot;Bypass&quot; (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular angioplasty/stenting</intervention_name>
    <description>Performing an angioplasty with or without stenting in stenosis.</description>
    <arm_group_label>Group &quot;Endovascular&quot; (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hybrid surgery</intervention_name>
    <description>Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.</description>
    <arm_group_label>Group &quot;Hybrid&quot; (C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <description>100 mg Vitamin E per os 1 per day (1 month).</description>
    <arm_group_label>Group &quot;Bypass&quot; (A)</arm_group_label>
    <arm_group_label>Group &quot;Endovascular&quot; (B)</arm_group_label>
    <arm_group_label>Group &quot;Hybrid&quot; (C)</arm_group_label>
    <other_name>Tocopherol acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Duplex ultrasound</intervention_name>
    <description>Duplex ultrasound of lower limbs arteries.</description>
    <arm_group_label>Group &quot;Bypass&quot; (A)</arm_group_label>
    <arm_group_label>Group &quot;Conservative&quot; (D)</arm_group_label>
    <arm_group_label>Group &quot;Endovascular&quot; (B)</arm_group_label>
    <arm_group_label>Group &quot;Healthy volunteers&quot; (E)</arm_group_label>
    <arm_group_label>Group &quot;Hybrid&quot; (C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling for apoptosis and endothelial dysfunction markers.</description>
    <arm_group_label>Group &quot;Bypass&quot; (A)</arm_group_label>
    <arm_group_label>Group &quot;Conservative&quot; (D)</arm_group_label>
    <arm_group_label>Group &quot;Endovascular&quot; (B)</arm_group_label>
    <arm_group_label>Group &quot;Healthy volunteers&quot; (E)</arm_group_label>
    <arm_group_label>Group &quot;Hybrid&quot; (C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Arterial wall sampling</intervention_name>
    <description>Arterial wall sampling for apoptosis markers.</description>
    <arm_group_label>Group &quot;Bypass&quot; (A)</arm_group_label>
    <arm_group_label>Group &quot;Hybrid&quot; (C)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atherosclerotic peripheral arterial disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  men or women over 40 years of age;&#xD;
&#xD;
          -  presence of atherosclerotic peripheral artery disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  men or women under 40 years of age;&#xD;
&#xD;
          -  chronic lower limb ischemia of a different etiology (disease Burger, aortoarteritis,&#xD;
             etc.),&#xD;
&#xD;
          -  active cancer or remission period less than 5 years;&#xD;
&#xD;
          -  decompensated diabetes mellitus;&#xD;
&#xD;
          -  pregnancy or breastfeeding in women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor A Suchkov, Sc.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ryazan State Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ryazan State Medical University</name>
      <address>
        <city>Ryazan'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atherosclerosis</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>apoptosis</keyword>
  <keyword>restenosis</keyword>
  <keyword>atherosclerotic plaque</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

